top of page
![Boston_H_color[33632]_edited.png](https://static.wixstatic.com/media/e60c5c_0b72738a80554196840094a8e387c5ed~mv2.png/v1/fill/w_338,h_77,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Boston_H_color%5B33632%5D_edited.png)
Preventing Recurrence and Improving Outcomes for Your Patients Following Resection of STAGE IIB/C MELANOMA
Thu, Apr 11
|Zoom link provided following registration
The Role of Adjuvant Immunotherapy Presented by Jason Luke, MD Associate Director for Clinical Research Director - Immunotherapy and Drug Development Center UPMC Hillman Cancer Center and University of Pittsburgh Pittsburgh, PA
Registration is closed
See other events
Time & Location
Apr 11, 2024, 12:00 PM – 1:00 PM
Zoom link provided following registration
Guests
About The Event
Link to Register with MedLearning: https://www.medlearninggroup.com/cme-programming/mel-echo5/
Learning Objectives:
Upon the completion of this program, attendees should be able to:
- Interpet data from studies evaluating the use of adjuvant immmunotherapy following resection of stage IIB/C Melanoma
- Facilitate the inclusion of adjuvant immunotherapy following resection of stage IIB/C Melanoma as a part of individualized patient management plans
- Prepare strategies for detecting and mitigating theirAEs associated with immunotherpaies used for the treatment of patients with early-stage melanoma
- Support multidisciplinary team approaches to the management of patients with early-stage melanoma
NURSES: Amedeco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
bottom of page